Chronic inflammation is recognized as a leading promoting factor of many diseases including carcinogenesis [
21], which continues to be the leading cause of mortality and disability around the world [
22,
23]. Inflammation was proposed as the seventh hallmark of cancer in 2009 [
24]. Cancer and inflammation are linked by intrinsic and extrinsic pathways. Intrinsically, oncogenes regulate the inflammatory microenvironment, whereas extrinsically, the inflammatory microenvironment promotes the growth and spread of cancer [
25]. Many of the cell types involved in chronic inflammation can be found in tumours, both in the surrounding stroma and within the tumour itself. Many neoplasms, including some of epithelial origin, contain a significant inflammatory cell component [
26]. Multiple studies on human clinical samples reveal that inflammation influences epithelial cell turnover [
27,
28]. Significantly, human susceptibility to breast, liver, large bowel, bladder, prostate, gastric mucosa, ovary, and skin carcinoma are increased when proliferation occurs in the context of chronic inflammation [
27,
28,
29,
30,
31,
32].
Chronic inflammation is linked to approximately 25% of all human cancers and increases cancer risks [
33] by stimulating angiogenesis and cell proliferation, inducing gene mutations and/or inhibiting apoptosis [
33]. Chronic inflammation can develop from acute inflammation if the irritant persists, although in most cases the response is chronic from the start. Chronic inflammation is characterized by the infiltration of injured tissue by mononuclear cells such as macrophages, lymphocytes, and plasma cells, as well as tissue destruction and attempts at repair [
26].
Helicobacter pylori infections in gastric cancer, human papillomavirus infections in cervical cancer, hepatitis B or C infections in hepatocellular carcinoma, and inflammatory bowel disease in colorectal cancer (CRC) are common causes of chronic inflammation associated with cancer development [
34,
35]. Inflammation also causes epigenetic changes that are linked to cancer development. Natural polyacetylenes from numerous food and medicinal plants and their derivatives exerted multiple bioactivities, including anti-inflammatory properties [
36]. Polyacetylene components can impact the inflammation through several known and unknown pathways.
2.1.1. Inhibition of Nuclear Factor kappa B (NF-κB) Pathways
NF-κB is a transcription factor that regulates the expression of many genes involved in the regulation of inflammation and autoimmune diseases [
37,
38]. Moreover, NF-κB plays a significant role in inflammation-induced cancers, as NF-κB is one of the major inflammatory pathways that are triggered by, for example, infections causing chronic inflammation [
34,
35,
39]. Cellular immunity, inflammation, and stress are all regulated by NF-κB signalling, as are cell differentiation, proliferation, and apoptosis (
Figure 2) [
40,
41]. Both solid and hematologic malignancies frequently modify the NF-κB pathway in ways that promote tumour cell proliferation and survival [
42,
43,
44].
NF-κB, a key factor in the inflammatory process, provides a mechanistic link between inflammation and cancer and the components of this pathway are targets for chemoprevention, particularly in CRC [
45]. There are two major signalling pathways for NF-κB activation, which are the canonical and the non-canonical NF-κB signalling pathways. The canonical pathway activates NF-κB1 p50, RELA and c-REL, which are also called canonical NF-κB family members. The non-canonical NF-κB pathway, on the other hand, selectively activates p100-sequestered NF-κB members, mostly NF-κB2 p52 and RELB, which are also called non-canonical NF-κB family members [
46]. LPS and proinflammatory cytokines, among other pathogenic substances, activate NF-κB through degrading Inhibitor of κB (IκBs) [
47] to release the common subunit P65 (RELA). In order to trigger the transcription of these genes, activated NF-κB travels into the nucleus and attaches to its associated DNA motifs. When activated, NF-κB p65 subunit binds to promoter regions of genes involved in inflammation, leading to the production of IL-6, IL-1β, and TNF-α [
48].
The carrot polyacetylenes, particularly (FaOH and FaDOH), the most abundant polyacetylenes in carrot, have been shown to reduce inflammation [
3,
49], in part by inhibiting the transcription factor NF-κB [
50]. Mice fed a diet containing FaOH were less likely to develop severe inflammation after being exposed to LPS [
5]. FaOH from ginseng significantly reduced the LPS induced TNF-α and IL-6 in cultured BV-2 microglia cells and murine serum [
47]. It has been demonstrated that FaOH and FaDOH purified from carrots have preventative effects on colorectal precancerous lesions in azoxymethane (AOM)-induced rats. Biopsies of neoplastic tissue were analysed for gene expression and the results showed that FaOH and FaDOH inhibited NF-κB and the downstream inflammatory markers TNF-α, IL-6, and COX-2 [
51]. A recent study has shown that FaOH from Radix Saposhnikoviae (dried roots of
Saposhnikovia divaricata, Apiaceae), inhibited LPS-induced NF-κB p65 activation and IκB-α phosphorylation in BV-2 microglia cells [
47]. Treatment using FaOH from the roots of
Heracleum moellendorffii inhibited LPS-induced NF-κB signalling activation by inhibiting IκB-α degradation and nuclear accumulation of p65 [
52] on RAW264.7 cells. In addition, FaDOH reduced level of LPS/IFNγ-induced NF-κB, IKK-α and IKK-β activation on rat primary astrocytes [
50].
Prostaglandin (PG) synthesis is a hallmark of inflammation. Two enzymes, cyclooxygenase (COX) 1 and 2, catalyse the first step of PG synthesis, but COX-2 is the major one that responds to inflammatory signal to produce PG at inflammatory sites [
53]. However, COX-2 can be suppressed by inhibiting the NF-kB translocation pathway (
Figure 2) [
54]. COX-2 expressions in healthy tissues are low, but can quickly increase in response to growth factors, cytokines, and signals promoting tumour invasion, metastasis, aberrant proliferation, and angiogenesis [
55]. Many malignancies, including colorectal [
56], bladder [
57], breast [
58], lung [
59], pancreatic [
60], prostate [
60], and head and neck cancer [
61], have been shown to be associated with elevated levels of COX-2. Mechanistically, COX-2 promotes carcinogenesis through the creation of prostaglandins (PGs), which suppress apoptosis and stimulate the development of blood vessels in tumour tissue which help sustaining tumour cell viability and growth [
34,
62], suggesting that anti-inflammatory drugs targeting COX-2 might be beneficiary in the treatment of many types of cancer.
It has been demonstrated that polyacetylenes modulate inflammation via suppressing COX-2, whose expression depends on NF-κB activation by inflammation [
63]. FaOH inhibited LPS-induced COX-2 expression in RAW264.7 cells thus blocking PGE2 overproduction [
52]. FaOH isolated from American ginseng effectively reduced the severity of colitis in mice treated with Dextran Sulfate Sodium (DSS). FaOH treatment prior to DSS did not prevent colitis in mice but FaOH decreased COX-2 expression level effectively when colitis was induced with DSS for one week then followed by FaOH treatment, suggesting that the polyacetylene component does have a therapeutic effect on colitis [
8]. Moreover, in azoxymethane (AOM)-induced rats colorectal cancer model, FaOH and FaDOH downregulated COX-2 in precancerous lesions of colorectal cancer (CRC) [
51] and also reduced the number of malignant tumour foci.